摘要
目的观察原发性肝癌(primary liver cancer,PLC)患者和健康志愿者清肝化瘀方含药血清对肝癌细胞SMMC-7721增殖、细胞凋亡、细胞周期的影响。方法采用四唑盐比色法[3-(4,5-dimethy-2 thiahiazoyl)-3,5-di-phenyl-tetrazolium bromide,MTT]法、流式细胞术比较PLC患者及健康志愿者服用清肝化瘀方药前后,含药血清对人肝癌细胞SMMC-7721增殖的抑制作用。结果培养48h,PLC患者清肝化瘀方含药血清对SMMC-7721细胞生长的抑制作用最明显,上调bax基因表达,下调bcl-2表达(P<0.05)。健康志愿者服药前后的血清对SMMC-7721细胞的生长均有抑制作用,但差异无统计学意义(P>0.05)。结论 PLC患者服用清肝化瘀方后的含药血清可显著抑制SMMC-7721细胞增殖并促进其凋亡。
Objective To investigate the serapharmacological effects of liver-clearing and stasis-removing on proliferation,apoptosis and cellular cycling of SMMC-7721 cell.Methods MTT and flow cytometry assay were used to compare the different effects between primary liver cancer (PLC) patients'and volunteers'serum on proliferation,apoptosis and cellular cycling of SMMC-7721 cell before and after liver-clearing and stasis-removing was administrated.Results The inhibitory effect of patient's serum on the proliferation of SMMC-7721 cell was the most significant in48h (P <0.01).And it could up-regulate the expression of bax gene and down-regulate the expression of bcl-2 gene.But the healthy volunteers'serum before and after liver-clearing and stasis-removing administration showed no significant inhibitory effect on SMMC-7721 proliferation.Conclusion The serum of PLC patients taken liver-clearing and stasis-removing could inhibit SMMC-7721 cell's proliferation.
出处
《河北医科大学学报》
CAS
2011年第5期501-504,共4页
Journal of Hebei Medical University
基金
河北省自然科学基金资助项目(303516)
关键词
清肝化瘀方
血清
肝肿瘤
liver-clearing and stasis-removing
serum
liver neoplasms